DZ Bank restated their neutral rating on shares of Carl Zeiss Meditec (ETR:AFX) in a research note issued to investors on Tuesday morning, Borsen Zeitung reports.
Several other analysts have also recently commented on the company. HSBC set a €109.00 ($126.74) target price on Carl Zeiss Meditec and gave the stock a neutral rating in a report on Tuesday. Kepler Capital Markets set a €80.00 ($93.02) price target on Carl Zeiss Meditec and gave the company a sell rating in a report on Friday, December 6th. Berenberg Bank set a €93.00 ($108.14) price target on Carl Zeiss Meditec and gave the company a neutral rating in a report on Friday, December 6th. Independent Research set a €93.00 ($108.14) price target on Carl Zeiss Meditec and gave the company a sell rating in a report on Tuesday. Finally, Nord/LB set a €98.00 ($113.95) price target on Carl Zeiss Meditec and gave the company a neutral rating in a report on Thursday, October 24th. Two analysts have rated the stock with a sell rating, three have issued a hold rating and three have given a buy rating to the company. Carl Zeiss Meditec presently has a consensus rating of Hold and a consensus price target of €105.71 ($122.92).
Shares of AFX stock opened at €111.90 ($130.12) on Tuesday. The stock’s fifty day moving average is €103.92 and its 200-day moving average is €98.05. The company has a debt-to-equity ratio of 4.55, a quick ratio of 3.09 and a current ratio of 4.11. The stock has a market capitalization of $10.01 billion and a PE ratio of 65.36. Carl Zeiss Meditec has a 52 week low of €65.80 ($76.51) and a 52 week high of €112.70 ($131.05).
Carl Zeiss Meditec AG operates as a medical technology company in Germany, the United States, Japan, other Europe countries, and internationally. It operates through two segments, Ophthalmic Devices and Microsurgery. The Ophthalmic Devices segment offers optical biometers, ophthalmic surgical microscopes, phacoemulsification/vitrectomy devices, intraocular lenses, and ophthalmic viscoelastic products for the diagnosis and treatment of ophthalmic diseases in the field of cataract and retinal surgery.
Read More: How does quantitative easing work?
Receive News & Ratings for Carl Zeiss Meditec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Carl Zeiss Meditec and related companies with MarketBeat.com's FREE daily email newsletter.